Evidence map›Paper›PMID 37713266›Full record

ReviewJournal of the National Cancer Institute2024

Prostate cancer screening in African American men: a review of the evidence.

Kevin H Kensler, Roman Johnson, Faith Morley, Mohamed Albrair, Barbra A Dickerman, Roman Gulati, Sarah K Holt, Hari S Iyer, Adam S Kibel, Jenney R Lee and 6 more

Open access · greenAbstract readReview
In one paragraph

Review in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cancer statistics, 2025.CA: a cancer journal for clinicians
    Article
  9. Prostate cancer statistics, 2025.CA: a cancer journal for clinicians
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Kevin H KenslerDepartment of Population Health Sciences, Weill Cornell Medical Center, New York, NY, USA.
Roman JohnsonCenter for Global Health, Massachusetts General Hospital, Boston, MA, USA.
Faith MorleyDepartment of Population Health Sciences, Weill Cornell Medical Center, New York, NY, USA.
Mohamed AlbrairDepartment of Global Health, University of Washington, Seattle, WA, USA.
Barbra A DickermanDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Roman GulatiDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-7592-6567
Sarah K HoltDepartment of Urology, University of Washington, Seattle, WA, USA.
Hari S IyerSection of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Adam S KibelDepartment of Urology, Brigham and Women's Hospital, Boston, MA, USA.
Jenney R LeeDepartment of Urology, University of Washington, Seattle, WA, USA.
Mark A PrestonDepartment of Urology, Brigham and Women's Hospital, Boston, MA, USA.
Jason L VassyVA Boston Healthcare System, Boston, MA, USA.
Erika M WolffDepartment of Urology, University of Washington, Seattle, WA, USA.
Yaw A NyameDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ruth EtzioniDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Timothy R RebbeckDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-4799-1900
University of Washington · USBrigham and Women's Hospital · USCornell University · USFred Hutch Cancer Center · USHarvard University · USMassachusetts General Hospital · USRutgers, The State University of New Jersey · US

Funding

Modeling Precision Interventions for Prostate Cancer ControlU01CA253915 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D, TSODIKOV, ALEXANDER · 2020 to 2025
$6.5M
Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI LU-YAO, GRACE · 2018 to 2020
$3.2M
Statistical modeling to support population and translational cancer researchR50CA221836 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Roman Gulati · 2017 to 2026
$2.0M
Contributions of tumor molecular subtypes to prostate cancer racial disparitiesR00CA245900 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KENSLER, KEVIN HUGHES · 2021 to 2023
$689k
Identifying optimal dynamic strategies for prostate cancer controlR00CA248335 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI DICKERMAN, BARBRA ANNE · 2022 to 2025
$688k
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A pragmatic trial of precision prostate cancer screeningI01CX002635 · VA · VA BOSTON HEALTH CARE SYSTEM · PI Jason L Vassy · 2024 to 2026
–
Building a shared decision making implementation strategy for the emerging paradigm of precision cancer screeningI01HX003627 · VA · EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL · PI Marla L. Clayman, Jason L Vassy · 2024 to 2026
–
CSRD VA I01 CX002635HSRD VA I01 HX003627NCI NIH HHS R00 CA245900NCI NIH HHS R00 CA248335NCI NIH HHS R50 CA221836NCI NIH HHS U01 CA253915NIH HHS P20CA233255
6 · The paper itself

Abstract

backgroundProstate cancer is the most diagnosed cancer in African American men, yet prostate cancer screening regimens in this group are poorly guided by existing evidence, given underrepresentation of African American men in prostate cancer screening trials. It is critical to optimize prostate cancer screening and early detection in this high-risk group because underdiagnosis may lead to later-stage cancers at diagnosis and higher mortality while overdiagnosis may lead to unnecessary treatment.

methodsWe performed a review of the literature related to prostate cancer screening and early detection specific to African American men to summarize the existing evidence available to guide health-care practice.

resultsLimited evidence from observational and modeling studies suggests that African American men should be screened for prostate cancer. Consideration should be given to initiating screening of African American men at younger ages (eg, 45-50 years) and at more frequent intervals relative to other racial groups in the United States. Screening intervals can be optimized by using a baseline prostate-specific antigen measurement in midlife. Finally, no evidence has indicated that African American men would benefit from screening beyond 75 years of age; in fact, this group may experience higher rates of overdiagnosis at older ages.

conclusionsThe evidence base for prostate cancer screening in African American men is limited by the lack of large, randomized studies. Our literature search supported the need for African American men to be screened for prostate cancer, for initiating screening at younger ages (45-50 years), and perhaps screening at more frequent intervals relative to men of other racial groups in the United States.

Indexed as

Prostatic NeoplasmsBlack or African AmericanEarly Detection of CancerHumansMaleMass ScreeningProstate-Specific AntigenUnited StatesProstate-Specific Antigen

Identifiers

PMID37713266
PMCPMC10777677
OpenAlexW4386757873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.